Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women

Climacteric

Volumn 6, Issue 2, 2003, Pages 104-111

  Wren, B G ^a   Day, R O ^b,d   McLachlan, A J ^c   Williams, K M ^d,e  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e ST VINCENT'S CLINIC   (Australia)

Author keywords

Buccal delivery; Postmenopausal symptoms; Sex hormones; Troche

Indexed keywords

ESTRADIOL; PRASTERONE; PROGESTERONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; CHEEK MUCOSA; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; FEMALE; FIRST PASS EFFECT; HORMONE SUBSTITUTION; HUMAN; LOZENGE; MENSTRUATION DISORDER; POSTMENOPAUSE; PRIORITY JOURNAL; SALIVA ANALYSIS; SUBSTITUTION THERAPY;

EID: 0038131743     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.6.2.104.111     Document Type: Article

References (30)

1. MacLennan AH, Taylor AW, Wilson DH. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995;162:420-2
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002;288:321-33
3. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopause estrogen and estrogen-progestin replacement therapy and breast cancer link. J Am Med Assoc 2000;283:485-91
4. Ross RR, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk. J Natl Cancer Inst 2000;92:328-32
5. Persson I, Yuen J, Bergvist L, Adami HO, Hoover R, Schairer C. Combined oestrogen-progestogen replacement therapy and breast cancer risk. Lancet 1992;350:1047-59
6. Lee JR. Osteoporosis reversal: the role of progesterone. Int Clin Nutr Rev 1990;10:384-9
7. Lee JR. Use of Pro-Gest cream in postmenopausal women (Letter). Lancet 1998;352:905
8. Whitehead MI, Townsend PT, Gill DK, Collins WD, Campbell S. Absorption and metabolism of oral progesterone. Br Med J 1980;1:825-7
9. Ross D, Cooper AJ, Pryse-Davies J, Bergeron C, Collins WP, Whitehead MI. Randomised double-blind, dose ranging study of the endometrial effects of a vaginal progesterone gel in estrogen treated postmenopausal women. Am J Obstet Gynecol 1997;177:937-41
10. Cooper A, Spencer C, Whitehad MI, Ross D, Barnard GJR, Collins WP. Systemic absorption of micronised progesterone from 'Progest' cream in postmenopausal women. Lancet 1998;351:1255-6
11. Leonetti HB, Longo S, Anasti JM. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-8
12. Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 2000;3:155-60
13. Sherwin BM, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective crossover study of sex steroid administration in surgical menopause. Psychosom Med 1997;47:339-51
14. Davis SR. Androgen treatment in women. Med J Aust 1999;170:545-9
15. Bruder JM, Sobek, Oette M. Dehydroepiandrosterone stimulates the estrogen response element. J Steroid Biochem Mol Biol 1997;62:461-6
16. Katz S, Morales AJ. Dehydroepiandrosterone (DHEA) and DHEA-sulphate (DS) as therapeutic options in menopause. Sem Reprod Endocrinol 1998;16:161-70
17. Labrie F. DHEA as a physiological replacement therapy at menopause. J Endocrinol Invest 1998;21:399-401
18. Shealy CN. A review of dehydroepiandrosterone (DHEA). Integ Physiol Behav Sci 1995;30:308-13
19. Raven PW, Hinson JP. DHEA and the menopause: a new approach to HRT? J Br Menopause Soc 2001;7:175-80
20. Studd J, Pornel B, Marton I, et al. Efficacy and acceptability of intranasal 17β-oestradiol for menopausal symptoms: randomised dose response study. Lancet 1999;353:1574-8
21. Gompel A, Bergeron C, Jondet M, et al. Endometrial safety and tolerability of Aerodiol. Maturitas 2000;34:209-15
22. Symposium Report. Aerodiol: pulsed estrogen therapy. Maturitas 2001;38(Suppl 1):S1-58
23. Dollbaum CM, Duwe GF. Absorption of progesterone after topical applications; serum and saliva levels. Presented at the 7th Annual Meeting of the American Menopause Society, September 1997, Chicago
24. De Lignieres B, Silberstein S. Pharmacodynamics of oestrogen and progestogens. Cephalalgia 2000;20:200-7
25. Ferenczy A, Bertrand G, Gelfand M. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 1997;133:859-67
26. Rosenfeld RS, Rosenberg BJ, Fukushima DK, Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulphate. J Clin Endocrinol Metab 1975;40:850-5
27. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-48
28. Slater CC, Souter I, Zhang C, Guan C, Stanczyk FZ, Mishell DR Jr. Pharmacokinetics of testosterone after percutaneous gel or buccal administration. Fertil Steril 2001;76:32-7
29. Koefoed P, Braham J. The permeability of the human red cell membrane to steroid sex hormones. Biochim Biophys Acta 1994:1195:55-62
30. Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurement to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 2001;41:1-6